Examkin

Question

Difficulty: HardPharmacological and Parenteral Therapies

A registered nurse is managing the care of a client with severe Crohn's disease who is receiving continuous Total Parenteral Nutrition (TPN) and a separate 20% intravenous fat emulsion (IVFE) via a multi-lumen central venous catheter. Which of the following interventions must the nurse implement to ensure the safe administration and monitoring of these therapies? Select all that apply.

  1. A
    Administer the 20% intravenous fat emulsion using an administration set equipped with a 0.22-micron inline filter.
  2. Monitor the client's capillary blood glucose levels every 4 to 6 hours throughout the infusion.Answer
  3. C
    Increase the TPN infusion rate temporarily to catch up if the infused volume falls behind the prescribed schedule.
  4. Hang an infusion of 10% dextrose in water (D10W) at the prescribed TPN rate if the current TPN bag empties before a replacement is available.Answer
  5. E
    Administer scheduled intravenous push medications through the dedicated TPN lumen to minimize catheter hub manipulation.
  6. Replace the administration sets and tubing for both the TPN and the intravenous fat emulsion every 24 hours.Answer

Answer

The correct interventions include monitoring blood glucose every 4 to 6 hours, hanging a D10W infusion if the TPN runs out, and replacing the administration sets every 24 hours.
Safe management of parenteral nutrition requires proactive nursing interventions to prevent metabolic, infectious, and mechanical complications. Routine capillary blood glucose monitoring every 4 to 6 hours is essential to detect TPN-induced hyperglycemia. If the primary TPN supply is interrupted, immediately hanging a 10% dextrose in water (D10W) solution at the prescribed rate prevents severe rebound hypoglycemia. Additionally, because intravenous lipid emulsions foster rapid bacterial and fungal growth, replacing all involved administration tubing every 24 hours is a critical, evidence-based infection control mandate.

Step-by-Step Solution

1
Evaluate the requirement for blood glucose monitoring during continuous TPN therapy.
Identify that TPN solutions have a high dextrose content, necessitating frequent glucose checks (every 4-6 hours) to prevent and appropriately manage hyperglycemia.
Maintaining euglycemia is critical for clients on parenteral nutrition to prevent complications such as osmotic diuresis, delayed wound healing, and infection.
2
Determine the appropriate clinical action if a TPN infusion is unexpectedly interrupted or delayed.
Recognize that abruptly stopping TPN causes profound rebound hypoglycemia. A D10W infusion must be initiated at the exact same rate to maintain blood glucose levels until the new TPN bag is prepared.
The pancreas continuously secretes high levels of endogenous insulin in response to the concentrated TPN; abrupt cessation of the glucose source while insulin levels remain high causes a rapid, dangerous drop in blood glucose.
3
Assess the strict infection control standards required for lipid emulsion administration.
Identify that any intravenous tubing used to administer lipid emulsions (IVFE) must be changed every 24 hours.
Lipids provide a nutrient-rich medium for microbial growth, significantly increasing the risk of central line-associated bloodstream infections if tubing is left in place longer than 24 hours.
4
Evaluate the distractors regarding inline filters, flow rate adjustments, and central line compatibility.
Recognize that lipids require a 1.2-micron filter (not a 0.22-micron filter), TPN infusion rates should never be increased to 'catch up', and the designated TPN lumen must remain exclusively dedicated.
These contraindicated actions compromise patient safety by increasing the risk of mechanical occlusion, severe metabolic derangements, and life-threatening precipitate formation in the central line.

Key Concept

Safe administration of Total Parenteral Nutrition (TPN) and lipids requires strict adherence to metabolic monitoring, infection control protocols, and intravenous compatibility guidelines to prevent life-threatening clinical complications.
Rate this question

Topics

Pharmacological and Parenteral Therapies

More questions from this topic